<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="751">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151380</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01625-36</org_study_id>
    <nct_id>NCT05151380</nct_id>
  </id_info>
  <brief_title>Clinical and Cyto-histological Evaluation of Fractional CO2 Laser Treatment on Genito-Urinary Syndromes of Menopause Related to Vaginal Atrophy</brief_title>
  <acronym>ATROVENANS</acronym>
  <official_title>Evaluation Clinique et Cyto-histologique du Traitement Laser CO2 fractionné Sur Les Syndromes Génito-Urinaires de la Ménopause liés à l'Atrophie Vaginale</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Nord Franche-Comte</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Nord Franche-Comte</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estrogen deficiency can occur naturally during menopause or as a secondary effect of various&#xD;
      treatments for breast or pelvic cancer and can lead to very disabling vulvovaginal symptoms,&#xD;
      since it is associated with an anatomical and functional cellular modification of the&#xD;
      urogenital sphere. These changes result in urogenital atrophy responsible for vaginal&#xD;
      dryness, painful intercourse (dyspareunia), discomfort, itching and burning sensations,&#xD;
      dysuria, urgency and incontinence. These symptoms, which significantly affect quality of&#xD;
      life, are found in more than 40% of menopausal women and are grouped under the term&#xD;
      Genitourinary Syndrome of Menopause (GSM). General or local estrogen-based treatments improve&#xD;
      patients' symptoms, but remain contraindicated in women who have had breast cancer.&#xD;
      Non-estrogenic local treatments are less effective, remain restrictive and are therefore&#xD;
      often abandoned.&#xD;
&#xD;
      The CO2 laser is currently part of the therapeutic arsenal for the management of patients&#xD;
      with GSM. This device prevents and eliminates the effects of low estrogen levels on vaginal&#xD;
      tissue by restoring the characteristic conditions of the vaginal mucosa of a woman of&#xD;
      childbearing age. This simple treatment, which lasts only a few minutes, is safe and painless&#xD;
      and has no serious side effects. It restores the tone and elasticity of the tissues, with&#xD;
      positive effects on the quality of life and the couple's relationship. We wish to evaluate&#xD;
      the possible changes of the genital sphere in a longitudinal way (before, during and after&#xD;
      the treatment), including the induced cytohistological changes, in patients with GSM who can&#xD;
      benefit of this therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective of the study is to analyze the evolution of GSM by the use of the MonaLisa Touch ® fractionated laser.</measure>
    <time_frame>3 months</time_frame>
    <description>The primary endpoint is the comparison of the patient's clinical score composed of a visual analogic scale measuring the intensity of symptoms related to vaginal atrophy (i.e., vaginal burning, vaginal pruritus, vaginal dryness, dyspareunia, and dysuria), before and after 3 laser sessions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>GSM Vaginal</condition>
  <condition>GSM Urinary</condition>
  <condition>GSM Non-vulvar</condition>
  <arm_group>
    <arm_group_label>Women with CO2 laser MonaLisa Touch ® sessions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women with 3 sessions of CO2 laser MonaLisa Touch ®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CO2 laser MonaLisa Touch ®</intervention_name>
    <description>3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed.&#xD;
The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice</description>
    <arm_group_label>Women with CO2 laser MonaLisa Touch ® sessions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women over 40 years of age&#xD;
&#xD;
          -  Patients with natural menopause or menopause secondary to cancer treatment (breast,&#xD;
             pelvis or other)&#xD;
&#xD;
          -  Patients with vaginal and/or urinary, non-vulvar GSM&#xD;
&#xD;
          -  Patients for whom CO2 laser therapy is proposed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vulvovaginal infections (vaginosis)&#xD;
&#xD;
          -  Uninvestigated vaginal hemorrhage&#xD;
&#xD;
          -  Herpes&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Cervico-vaginal pathology (cervical and/or vaginal dysplasia)&#xD;
&#xD;
          -  Suspected or diagnosed HPV&#xD;
&#xD;
          -  Significant vaginal prolapse&#xD;
&#xD;
          -  Patients on hormone replacement therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elodie BOUVIER</last_name>
    <email>elodie.bouvier@hnfc.fr</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

